uniQure N.V. (NASDAQ:QURE)‘s stock had its “buy” rating reissued by equities researchers at Cowen and Company in a research report issued on Wednesday, May 24th.
The analysts wrote, “QURE reported 1Q17 financials and presented multiple updates at ASGCT recently.””
QURE has been the topic of several other reports. Chardan Capital reissued a “positive” rating and set a $12.00 price target on shares of uniQure N.V. in a research report on Monday, January 30th. Zacks Investment Research cut shares of uniQure N.V. from a “buy” rating to a “sell” rating in a research report on Wednesday, May 17th. Jefferies Group LLC reissued a “hold” rating and set a $8.00 price target on shares of uniQure N.V. in a research report on Wednesday, April 12th. Finally, Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of uniQure N.V. in a research report on Wednesday, March 22nd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $15.28.
Shares of uniQure N.V. (QURE) traded down 2.72% during mid-day trading on Wednesday, hitting $5.00. The company had a trading volume of 125,514 shares. uniQure N.V. has a one year low of $4.72 and a one year high of $9.72. The company’s market capitalization is $127.22 million. The firm’s 50-day moving average price is $5.27 and its 200 day moving average price is $5.73.
uniQure N.V. (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.64) by $0.16. uniQure N.V. had a negative return on equity of 103.26% and a negative net margin of 223.38%. The business had revenue of $3.32 million for the quarter, compared to the consensus estimate of $4.20 million. Analysts predict that uniQure N.V. will post ($3.40) earnings per share for the current fiscal year.
WARNING: “uniQure N.V. (QURE) Earns “Buy” Rating from Cowen and Company” was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2017/06/17/uniqure-nvs-qure-buy-rating-reaffirmed-at-cowen-and-company-updated-updated.html.
Large investors have recently modified their holdings of the stock. Perceptive Advisors LLC purchased a new stake in shares of uniQure N.V. during the fourth quarter worth about $7,089,000. FMR LLC boosted its position in uniQure N.V. by 27.5% in the first quarter. FMR LLC now owns 1,498,463 shares of the biotechnology company’s stock valued at $8,661,000 after buying an additional 323,345 shares in the last quarter. City Financial Investment Co Ltd bought a new position in uniQure N.V. during the fourth quarter valued at $1,492,000. Baker BROS. Advisors LP bought a new position in uniQure N.V. during the third quarter valued at $1,760,000. Finally, P.A.W. Capital Corp bought a new position in uniQure N.V. during the first quarter valued at $867,000. 30.54% of the stock is currently owned by institutional investors.
uniQure N.V. Company Profile
uniQure N.V. (uniQure) is a gene therapy company. The Company is engaged in developing single treatments with curative results for patients suffering from genetic and other severe diseases. The Company is advancing a focused pipeline of gene therapies that have been developed both internally and through partnerships.
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.